Research area
Type 2 diabetes and lipid-induced nephrotoxicity in diabetic kidney disease.
Current research
The effects of the ABCA1 inducer R3R01 on albuminuria levels in diabetic kidney disease (the kidney ABC study):
A randomized controlled trial evaluating the effect of 3 months treatment with the drug R3R01 on albuminuria in people with type 2 diabetes and diabetic kidney disease with moderate to severe albuminuria and eGFR above 30 ml/min/1.73m2.
Lipidomics and diabetic kidney disease:
A cohort study investigating if lipidomics can increase our ability to understand and predict the development of diabetic kidney disease over a period of 5 years in patients with type 2 diabetes, albuminuria and normal eGFR.